Vanguard National Trust
DFTX

Vanguard National Trust’s Definium Therapeutics DFTX Stock Holding History

Vanguard National Trust’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27K Hold
27
– – ﹤0.01% 745
2026
Q1 		$510 Buy
+27
New +$458 ﹤0.01% 733

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard National Trust's DFTX Position: Q2 2026 in Review

Vanguard National Trust held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 27 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #745.

Vanguard National Trust first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 358 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Vanguard National Trust held 27 shares of Definium Therapeutics worth $1.27K as of Q2 2026.
  • Vanguard National Trust left its Definium Therapeutics share count unchanged in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #745 holding.
  • Vanguard National Trust first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 358 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.